Back to search results
NCT07218952

Radiation Therapy (RT) for Parkinson's Disease (PD)

Enrolling by Invitation
NAAges 45–70InterventionalTreatment
Mayo Clinic
~20 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:Radiation therapy

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in progression of Parkinson's Disease
Measured over Baseline, 6 months

Conditions

Parkinson's Disease

Explore related trials

Parkinson Disease

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Yasamin Sharifzadeh-Moghaddam · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 45 and ≤ 70 years
Diagnosis of Parkinson's disease by a Movement Disorder Neurologist
Confirmation of unilateral Parkinson's disease by Dopamine Transporter (DaT) scan
A score of 2 or less on the modified Hoehn and Yahr scale
ECOG Performance Status (PS) ≤ 2 (Appendix I).
No known genetic causes or predisposition to Parkinson's disease or related diseases.
Ability to complete questionnaires, neurological exam, and follow-up imaging independently or with assistance
Ability to provide written informed consent
Willing to provide mandatory blood samples for correlative research purposes
Willing to return to enrolling institution for follow-up

Exclusion

Concomitant dementia diagnosis or concerns of other memory disorder
Parkinson's Disease medication changes within the last 3 months
Receipt of radiation therapy for Parkinson's Disease outside Mayo Clinic, Rochester

What this trial measures

  • Change in progression of Parkinson's DiseaseBaseline, 6 months

    Slowing of progression will be defined as a 7-point decrease in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Motor Examination (physician-assessed motor symptoms) score. The score for this scale ranges from 0 to 132, with higher numbers indicating worse disease.